CP, I am aware of all the studies you cited. In fact I read all the patents applied for and approved before the studies even commenced. The early trials you cited only showed the promise of Bavi. In fact they showed that Bavi was not a silver bullet only a useful adjunct to the existing standard of care.
As you are well aware, early studies often show promise, and then the drug fails in more advanced trials. In 2010/11 Bavi was in the same position.
No sensible BP would risk the financial, legal and public relations disaster of the Fargo conspiracy to keep Bavi, or any of the dozens of promising early drug candidates, from completing a Phase II trial IMO.
Sorry, this just doesn't make sense to me.
GLTA, Paul